KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Cash (2016 - 2025)

Historic Change in Cash for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$2.0 million.

  • Nektar Therapeutics' Change in Cash fell 19017.98% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 13137.71%. This contributed to the annual value of $9.0 million for FY2024, which is 11695.0% up from last year.
  • Nektar Therapeutics' Change in Cash amounted to -$2.0 million in Q3 2025, which was down 19017.98% from $4.1 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Change in Cash registered a high of $42.8 million during Q1 2022, and its lowest value of -$98.3 million during Q3 2021.
  • Over the past 5 years, Nektar Therapeutics' median Change in Cash value was -$2.0 million (recorded in 2025), while the average stood at -$8.3 million.
  • In the last 5 years, Nektar Therapeutics' Change in Cash crashed by 406115.11% in 2021 and then surged by 33796.42% in 2022.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Change in Cash stood at -$28.8 million in 2021, then surged by 39.13% to -$17.5 million in 2022, then crashed by 69.09% to -$29.6 million in 2023, then skyrocketed by 147.71% to $14.1 million in 2024, then tumbled by 113.83% to -$2.0 million in 2025.
  • Its Change in Cash stands at -$2.0 million for Q3 2025, versus $4.1 million for Q2 2025 and -$5.4 million for Q1 2025.